首页 > 最新文献

中华妇产科杂志最新文献

英文 中文
[Updates of FIGO 2023 staging of endometrial cancer and its clinical-pathological significance]. [更新 FIGO 2023 子宫内膜癌分期及其临床病理学意义]。
Pub Date : 2024-03-25 DOI: 10.3760/cma.j.cn112141-20231127-00228
Y Song, A J Liu
{"title":"[Updates of FIGO 2023 staging of endometrial cancer and its clinical-pathological significance].","authors":"Y Song, A J Liu","doi":"10.3760/cma.j.cn112141-20231127-00228","DOIUrl":"10.3760/cma.j.cn112141-20231127-00228","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 3","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical practice guidelines for reconstruction of female external genitalia in China (2024)]. [中国女性外生殖器重建临床实践指南(2024 年)]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20231017-00155
{"title":"[Clinical practice guidelines for reconstruction of female external genitalia in China (2024)].","authors":"","doi":"10.3760/cma.j.cn112141-20231017-00155","DOIUrl":"10.3760/cma.j.cn112141-20231017-00155","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"108-117"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Lower urinary tract injury in transvaginal reconstructive pelvic surgery]. [经阴道骨盆重建手术中的下尿路损伤]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20231119-00206
W J Shen, Y X Lu, K Niu, Y H Zhang, W Y Wang, Y Zhao, J Ge, X L Zhang

Objective: To explore the characteristics, prevention and treatment strategies of lower urinary tract injury in transvaginal reconstructive pelvic surgery (vRPS). Methods: A retrospective analysis was conducted on 24 patients who suffered lower urinary tract injuries occuring in vRPS from January 2005 to June 2021, among which 4 cases were referred to our hospital from other hospitals. Results: (1) In our hospital, 1 952 patients underwent vRPS for anterior and (or) middle pelvic organ prolapse during that study period, with a 1.0% (20/1 952) incidence of lower urinary tract injuries occurring in 20 cases. (2) Ureteral injuries were observed in 14 cases who underwent transvaginal high uterosacral ligament suspension (1.4%, 14/966). The symptoms were relieved after the removal of sutures. (3) Bladder injuries occurred in 6 cases in our hospital, with 4 cases (0.7%, 4/576) in anterior transvaginal mesh surgery (aTVM), one (0.4%, 1/260) in colpocleisis, and one (0.7%, 1/150) in apical suspension for fornix prolapse. An additional 4 cases of bladder injury were referred to our hospital after aTVM. Among the 8 cases of bladder injury during aTVM, 2 cases were intraoperative incidents. Cystoscopy confirmed that the superficial branch or puncture rod of anterior vaginal mesh had penetrated into the bladder. Re-puncturing and placement of the mesh were successfully performed. No abnormalities were observed during a follow-up period of 4-5 years. Postoperative bladder injuries were identified in 6 cases, characterized by mesh erosion into the bladder and formation of calculi. These injuries were confirmed between 6 months to 2 years after vRPS. The exposed mesh and calculi in the bladder were removed through laparotomy or cystoscopy, followed up for 2-12 years. One case experienced slight re-erosion of mesh to the bladder. Conclusions: Lower urinary tract injuries are difficult to avoid in vRPS, particularly in transvaginal high uterosacral ligament suspension and aTVM. However, the incidence is low. Lower urinary tract injuries during vRPS could be easily detected and managed intraoperatively because of the use of cystoscopy. As long-term postoperative complications, erosion of transvaginal mesh to lower urinary tract postoperatively could be treated correctly, seldom with severe sequelae.

目的探讨经阴道盆腔重建手术(vRPS)中下尿路损伤的特点、预防和治疗策略。方法回顾性分析2005年1月至2021年6月在vRPS中发生下尿路损伤的24例患者,其中4例由其他医院转诊至我院。结果:(1)在该研究期间,我院有1 952例患者因前部和(或)中部盆腔脏器脱垂接受了vRPS手术,其中20例发生了下尿路损伤,发生率为1.0%(20/1 952)。(2) 14 例接受经阴道子宫骶骨高位韧带悬吊术的患者出现输尿管损伤(1.4%,14/966)。拆线后症状缓解。(3) 本院有 6 例膀胱损伤,其中 4 例(0.7%,4/576)发生在经阴道前部网片手术(aTVM)中,1 例(0.4%,1/260)发生在阴道结肠切除术中,1 例(0.7%,1/150)发生在穹窿脱垂的顶端悬吊术中。另有 4 例膀胱损伤病例是在 TVM 后转诊至我院的。8 例膀胱损伤病例中,2 例为术中损伤。膀胱镜检查证实,阴道前壁网片的浅表分支或穿刺棒已穿入膀胱。重新穿刺和放置网片的工作顺利完成。在 4-5 年的随访期间未发现异常。有 6 例患者术后出现膀胱损伤,主要表现为网片侵蚀膀胱并形成结石。这些损伤在 vRPS 术后 6 个月至 2 年间得到证实。通过开腹手术或膀胱镜将暴露在外的网片和膀胱内的结石取出,并随访 2-12 年。有一个病例的网片与膀胱发生了轻微的再侵蚀。结论:下尿路损伤在vRPS中很难避免,尤其是经阴道子宫骶骨高位韧带悬吊术和aTVM。不过,其发生率很低。由于使用了膀胱镜,vRPS术中的下尿路损伤很容易在术中被发现和处理。作为术后长期并发症,术后经阴道网片对下尿路的侵蚀可以得到正确处理,很少出现严重后遗症。
{"title":"[Lower urinary tract injury in transvaginal reconstructive pelvic surgery].","authors":"W J Shen, Y X Lu, K Niu, Y H Zhang, W Y Wang, Y Zhao, J Ge, X L Zhang","doi":"10.3760/cma.j.cn112141-20231119-00206","DOIUrl":"10.3760/cma.j.cn112141-20231119-00206","url":null,"abstract":"<p><p><b>Objective:</b> To explore the characteristics, prevention and treatment strategies of lower urinary tract injury in transvaginal reconstructive pelvic surgery (vRPS). <b>Methods:</b> A retrospective analysis was conducted on 24 patients who suffered lower urinary tract injuries occuring in vRPS from January 2005 to June 2021, among which 4 cases were referred to our hospital from other hospitals. <b>Results:</b> (1) In our hospital, 1 952 patients underwent vRPS for anterior and (or) middle pelvic organ prolapse during that study period, with a 1.0% (20/1 952) incidence of lower urinary tract injuries occurring in 20 cases. (2) Ureteral injuries were observed in 14 cases who underwent transvaginal high uterosacral ligament suspension (1.4%, 14/966). The symptoms were relieved after the removal of sutures. (3) Bladder injuries occurred in 6 cases in our hospital, with 4 cases (0.7%, 4/576) in anterior transvaginal mesh surgery (aTVM), one (0.4%, 1/260) in colpocleisis, and one (0.7%, 1/150) in apical suspension for fornix prolapse. An additional 4 cases of bladder injury were referred to our hospital after aTVM. Among the 8 cases of bladder injury during aTVM, 2 cases were intraoperative incidents. Cystoscopy confirmed that the superficial branch or puncture rod of anterior vaginal mesh had penetrated into the bladder. Re-puncturing and placement of the mesh were successfully performed. No abnormalities were observed during a follow-up period of 4-5 years. Postoperative bladder injuries were identified in 6 cases, characterized by mesh erosion into the bladder and formation of calculi. These injuries were confirmed between 6 months to 2 years after vRPS. The exposed mesh and calculi in the bladder were removed through laparotomy or cystoscopy, followed up for 2-12 years. One case experienced slight re-erosion of mesh to the bladder. <b>Conclusions:</b> Lower urinary tract injuries are difficult to avoid in vRPS, particularly in transvaginal high uterosacral ligament suspension and aTVM. However, the incidence is low. Lower urinary tract injuries during vRPS could be easily detected and managed intraoperatively because of the use of cystoscopy. As long-term postoperative complications, erosion of transvaginal mesh to lower urinary tract postoperatively could be treated correctly, seldom with severe sequelae.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"130-134"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Feasibility study of expectant management of different degrees of vaginal fluid in pregnant women with premature rupture of membranes in the second trimester]. [妊娠后三个月胎膜早破孕妇不同程度阴道积液预期管理的可行性研究]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20230915-00100
Y M Gao, S H Wu, H X Shang, Y L Yang, B H Zhou, X Yang

Objective: To investigate the feasibility of expectant management of different degrees of vaginal fluid in pregnant women with premature rupture of membranes in the second trimester. Methods: A retrospective cohort study was conducted to collect 103 pregnant women who were diagnosed with premature rupture of membranes in the second trimester of pregnancy and insisted on continuing the pregnancy in Shanxi Bethune Hospital from July 2012 to July 2022. According to the degree of vaginal fluid, pregnant women were divided into rupture group (with typical vaginal fluid, 48 cases) and leakage group (without typical vaginal fluid, 55 cases). The rupture latency (the time from rupture of membranes to termination of pregnancy), gestational weeks of termination, indications and methods of termination of pregnancy, maternal infection related indicators and perinatal outcomes were compared between the two groups. Univariate regression model was used to analyze the correlation between different degrees of vaginal fluid in pregnant women with premature rupture of membranes and maternal and neonatal outcomes. Results: (1) Obstetric indicators: there was no significant difference in the gestational age of rupture of membranes between the two groups (P>0.05). However, the proportion of rupture latency >28 days in the leakage group was significantly higher than that in the rupture group [42% (23/55) vs 13% (6/48); χ2=33.673, P<0.001], and the incidence of pregnancy termination ≥28 weeks was significantly higher [47% (26/55) vs 19% (9/48); χ2=9.295, P=0.002]. (2) Indications and methods of termination: the incidence of progressive reduction of amniotic fluid as the indication for termination in the leakage group was significantly lower than that in the rupture group [22% (12/55) vs 42% (20/48); χ2=4.715, P=0.030], and the incidence of full-term termination in the leakage group was significantly higher than that in the rupture group [31% (17/55) vs 12% (6/48); χ2=5.008, P=0.025], while there were no significant differences in the indications of termination of pregnancy, including amniotic cavity infection, uterine contraction failure and fetal distress between the two groups (all P>0.05). The incidence of induced labor or spontaneous contraction in the leakage group was significantly lower than that in the rupture group [53% (29/55) vs 81% (39/48); χ2=9.295, P=0.002], while the cesarean section rate and vaginal delivery rate were similar between the two groups (both P>0.05). (3) Infection related indicators: the incidence of amniotic cavity infection in the leakage group was significantly higher than that in the rupture group [31% (17/55) vs 13% (6/48); χ2=4.003, P=0.045]. However, there were no significant differences in the elevation of inflammatory indicators, t

目的探究对第二孕期胎膜早破孕妇不同程度阴道积液进行预期管理的可行性。方法:对 103 名胎膜早破孕妇进行回顾性队列研究:通过回顾性队列研究,收集2012年7月-2022年7月在山西白求恩医院确诊为胎膜早破并坚持继续妊娠的103例孕妇。根据阴道积液程度将孕妇分为破膜组(有典型阴道积液,48 例)和漏液组(无典型阴道积液,55 例)。比较了两组孕妇的胎膜破裂潜伏期(从胎膜破裂到终止妊娠的时间)、终止妊娠的孕周、终止妊娠的指征和方法、母体感染相关指标和围产儿结局。采用单变量回归模型分析胎膜早破孕妇不同程度阴道积液与孕产妇及新生儿结局的相关性。结果:(1)产科指标:两组胎膜破裂胎龄差异无学意义(P>0.05)。但漏破组破裂潜伏期>28天的比例明显高于破膜组[42%(23/55)vs 13%(6/48);χ2=33.673,Pχ2=9.295,P=0.002]。(2)终止妊娠的指征与方法:漏胎组以羊水进行性减少作为终止妊娠指征的发生率明显低于破裂组[22%(12/55) vs 42%(20/48);χ2=4.715,P=0.030],漏产组足月终止妊娠的发生率明显高于破裂组[31%(17/55) vs 12%(6/48);χ2=5.008,P=0.025],而两组患者终止妊娠的指征包括羊膜腔感染、子宫收缩乏力、胎儿窘迫等无明显差异(均P>0.05)。漏产组引产或自然宫缩发生率明显低于破裂组[53%(29/55)vs 81%(39/48);χ2=9.295,P=0.002],两组剖宫产率和阴道分娩率相似(均P>0.05)。(3)感染相关指标:漏破组羊膜腔感染发生率明显高于破裂组[31%(17/55)vs 13%(6/48);χ2=4.003,P=0.045]。但两组间炎症指标升高、宫颈分泌物细菌培养阳性率和组织绒毛膜羊膜炎发生率无明显差异(均 P>0.05)。(4)围产期结局:漏吸组的活产率明显高于破裂组[51%(28/55)vs 27%(13/48);χ2=5.119,P=0.024]。漏产组 1 分钟 Apgar 评分大于 7 分的活产婴儿比例明显高于破裂组 [38% (21/55) vs 17% (8/48);χ2=4.850,P=0.028]。然而,两组间活产婴儿的出生体重和新生儿并发症的发生率无明显差异(P>0.05)。(5)单变量回归分析显示,与破裂组相比,漏尿组妊娠周数≥28孕周终止妊娠(RR=2.521,95%CI:1.314-4.838;P=0.002)、羊膜感染(RR=2.473,95%CI:1.061-5.764;P=0.025)、围产儿存活率(RR=1.880,95%CI:1.104-3.199;P=0.014)的风险更高。结论与胎膜早破第二孕期典型阴道积液孕妇相比,非典型阴道积液孕妇的期待治疗更为可行,可有效延长孕周,提高围产儿活产率。
{"title":"[Feasibility study of expectant management of different degrees of vaginal fluid in pregnant women with premature rupture of membranes in the second trimester].","authors":"Y M Gao, S H Wu, H X Shang, Y L Yang, B H Zhou, X Yang","doi":"10.3760/cma.j.cn112141-20230915-00100","DOIUrl":"10.3760/cma.j.cn112141-20230915-00100","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the feasibility of expectant management of different degrees of vaginal fluid in pregnant women with premature rupture of membranes in the second trimester. <b>Methods:</b> A retrospective cohort study was conducted to collect 103 pregnant women who were diagnosed with premature rupture of membranes in the second trimester of pregnancy and insisted on continuing the pregnancy in Shanxi Bethune Hospital from July 2012 to July 2022. According to the degree of vaginal fluid, pregnant women were divided into rupture group (with typical vaginal fluid, 48 cases) and leakage group (without typical vaginal fluid, 55 cases). The rupture latency (the time from rupture of membranes to termination of pregnancy), gestational weeks of termination, indications and methods of termination of pregnancy, maternal infection related indicators and perinatal outcomes were compared between the two groups. Univariate regression model was used to analyze the correlation between different degrees of vaginal fluid in pregnant women with premature rupture of membranes and maternal and neonatal outcomes. <b>Results:</b> (1) Obstetric indicators: there was no significant difference in the gestational age of rupture of membranes between the two groups (<i>P</i>>0.05). However, the proportion of rupture latency >28 days in the leakage group was significantly higher than that in the rupture group [42% (23/55) vs 13% (6/48); <i>χ</i><sup>2</sup><i>=</i>33.673, <i>P</i><0.001], and the incidence of pregnancy termination ≥28 weeks was significantly higher [47% (26/55) vs 19% (9/48); <i>χ</i><sup>2</sup>=9.295, <i>P</i>=0.002]. (2) Indications and methods of termination: the incidence of progressive reduction of amniotic fluid as the indication for termination in the leakage group was significantly lower than that in the rupture group [22% (12/55) vs 42% (20/48); <i>χ</i><sup>2</sup>=4.715, <i>P</i>=0.030], and the incidence of full-term termination in the leakage group was significantly higher than that in the rupture group [31% (17/55) vs 12% (6/48); <i>χ</i><sup>2</sup>=5.008, <i>P</i>=0.025], while there were no significant differences in the indications of termination of pregnancy, including amniotic cavity infection, uterine contraction failure and fetal distress between the two groups (all <i>P</i>>0.05). The incidence of induced labor or spontaneous contraction in the leakage group was significantly lower than that in the rupture group [53% (29/55) vs 81% (39/48); <i>χ</i><sup>2</sup>=9.295, <i>P</i>=0.002], while the cesarean section rate and vaginal delivery rate were similar between the two groups (both <i>P</i>>0.05). (3) Infection related indicators: the incidence of amniotic cavity infection in the leakage group was significantly higher than that in the rupture group [31% (17/55) vs 13% (6/48); <i>χ</i><sup>2</sup>=4.003, <i>P</i>=0.045]. However, there were no significant differences in the elevation of inflammatory indicators, t","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"121-129"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Guidelines for clinical diagnosis, treatment and management of intrahepatic cholestasis of pregnancy (2024)]. [妊娠期肝内胆汁淤积症临床诊断、治疗和管理指南(2024 年)]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20230914-00099
{"title":"[Guidelines for clinical diagnosis, treatment and management of intrahepatic cholestasis of pregnancy (2024)].","authors":"","doi":"10.3760/cma.j.cn112141-20230914-00099","DOIUrl":"10.3760/cma.j.cn112141-20230914-00099","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"97-107"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[In heritance and innovation in the diagnosis and treatment of malignant ovarian germ cell tumors]. [恶性卵巢生殖细胞瘤诊断和治疗的传承与创新]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20230926-00118
J X Yang, J H Lang
{"title":"[In heritance and innovation in the diagnosis and treatment of malignant ovarian germ cell tumors].","authors":"J X Yang, J H Lang","doi":"10.3760/cma.j.cn112141-20230926-00118","DOIUrl":"10.3760/cma.j.cn112141-20230926-00118","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"118-120"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Oncological outcomes of laparoscopic radical trachelectomy for early stage cervical cancer]. [早期宫颈癌腹腔镜根治性气管切除术的肿瘤学效果]。
Pub Date : 2024-02-25 DOI: 10.3760/cma.j.cn112141-20231115-00195
Q Liu, Y X Sun, K J Liu, P Q Li, X X Zhao, Z J Hu

Objective: To analyze and summarize the oncological outcomes after laparoscopic radical trachelectomy (LRT) for early stage cervical cancer. Methods: The clinical data and follow-up results of 148 patients with early stage cervical cancer who underwent LRT in Renji Hospital, School of Medicine, Shanghai Jiao Tong University from July 2014 to June 2023 were collected, while tumor outcomes and postoperative pregnancy were analyzed retrospectively. Results: (1) General situation: the median age of 148 patients with LRT was 33 years (range: 19-42 years). Pathological type: 111 cases of squamous cell carcinoma, 36 cases of adenocarcinoma, 1 case of adenosquamous carcinoma. International Federation of Gynecology and Obstetrics (2018) stage: 17 cases of stage Ⅰa1 with lympho-vascular space invasion, 25 cases of stage Ⅰa2, 102 cases of stage Ⅰb1, and 4 cases of stage Ⅰb2. (2) Tumor outcomes: 148 patients were followed up regularly after LRT, and the median follow-up time was 59 months (range: 2-104 months). During the follow-up period, 5 cases of tumor recurred (including 1 death), and the median recurrence time was 10 months (range: 4-33 months). Among them, there were 3 cases of pelvic metastasis, 1 case of distant metastasis, and 1 case of both pelvic and distant metastasis. Both 3-year and 5-year disease-free survival rates of 148 patients were 94.5%, and the 5-year overall survival rate was 98.9%. (3) Postoperative pregnancy: among 148 patients with LRT, 67 patients had pregnancy requirements, followed up for 1 year, and 20 of them were pregnant, with a pregnancy rate of 29.9% (20/67). Among the 20 pregnant patients, 2 cases early abortion, 1 case mid-term abortion, and 17 cases gave birth (including 4 cases of premature birth and 13 cases of full-term birth). Conclusion: Under the condition of strict control of surgical indications, guaranteed surgical scope and tumor-free operation, LRT in patients with early cervical cancer has a good outcome.

目的分析并总结早期宫颈癌腹腔镜根治性气管切除术(LRT)的肿瘤治疗效果。方法:对 148 例早期宫颈癌患者的临床数据和随访结果进行分析:收集2014年7月-2023年6月在上海交通大学医学院附属仁济医院接受LRT治疗的148例早期宫颈癌患者的临床资料和随访结果,并对肿瘤预后和术后妊娠情况进行回顾性分析。结果:(1)一般情况:148 例 LRT 患者的中位年龄为 33 岁(范围:19-42 岁)。病理类型:鳞状细胞癌 111 例,腺癌 36 例,腺鳞癌 1 例。国际妇产科联盟(2018)分期:Ⅰa1期伴淋巴管间隙侵犯17例,Ⅰa2期25例,Ⅰb1期102例,Ⅰb2期4例。 (2)肿瘤结局:148 例患者在 LRT 后接受了定期随访,中位随访时间为 59 个月(范围:2-104 个月)。随访期间,5 例肿瘤复发(包括 1 例死亡),中位复发时间为 10 个月(范围:4-33 个月)。其中,盆腔转移 3 例,远处转移 1 例,盆腔和远处均转移 1 例。148例患者的3年和5年无病生存率均为94.5%,5年总生存率为98.9%。(3)术后妊娠:在148例LRT患者中,67例患者有妊娠要求,随访1年,其中20例妊娠,妊娠率为29.9%(20/67)。20 例妊娠患者中,早期流产 2 例,中期流产 1 例,分娩 17 例(其中早产 4 例,足月分娩 13 例)。结论在严格控制手术指征、保证手术范围和无肿瘤的情况下,早期宫颈癌患者的 LRT 治疗效果良好。
{"title":"[Oncological outcomes of laparoscopic radical trachelectomy for early stage cervical cancer].","authors":"Q Liu, Y X Sun, K J Liu, P Q Li, X X Zhao, Z J Hu","doi":"10.3760/cma.j.cn112141-20231115-00195","DOIUrl":"10.3760/cma.j.cn112141-20231115-00195","url":null,"abstract":"<p><p><b>Objective:</b> To analyze and summarize the oncological outcomes after laparoscopic radical trachelectomy (LRT) for early stage cervical cancer. <b>Methods:</b> The clinical data and follow-up results of 148 patients with early stage cervical cancer who underwent LRT in Renji Hospital, School of Medicine, Shanghai Jiao Tong University from July 2014 to June 2023 were collected, while tumor outcomes and postoperative pregnancy were analyzed retrospectively. <b>Results:</b> (1) General situation: the median age of 148 patients with LRT was 33 years (range: 19-42 years). Pathological type: 111 cases of squamous cell carcinoma, 36 cases of adenocarcinoma, 1 case of adenosquamous carcinoma. International Federation of Gynecology and Obstetrics (2018) stage: 17 cases of stage Ⅰa1 with lympho-vascular space invasion, 25 cases of stage Ⅰa2, 102 cases of stage Ⅰb1, and 4 cases of stage Ⅰb2. (2) Tumor outcomes: 148 patients were followed up regularly after LRT, and the median follow-up time was 59 months (range: 2-104 months). During the follow-up period, 5 cases of tumor recurred (including 1 death), and the median recurrence time was 10 months (range: 4-33 months). Among them, there were 3 cases of pelvic metastasis, 1 case of distant metastasis, and 1 case of both pelvic and distant metastasis. Both 3-year and 5-year disease-free survival rates of 148 patients were 94.5%, and the 5-year overall survival rate was 98.9%. (3) Postoperative pregnancy: among 148 patients with LRT, 67 patients had pregnancy requirements, followed up for 1 year, and 20 of them were pregnant, with a pregnancy rate of 29.9% (20/67). Among the 20 pregnant patients, 2 cases early abortion, 1 case mid-term abortion, and 17 cases gave birth (including 4 cases of premature birth and 13 cases of full-term birth). <b>Conclusion:</b> Under the condition of strict control of surgical indications, guaranteed surgical scope and tumor-free operation, LRT in patients with early cervical cancer has a good outcome.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 2","pages":"135-142"},"PeriodicalIF":0.0,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Guideline of diagnosis and management of amenorrhea (2023)]. [闭经的诊断和管理指南(2023 年)]。
Pub Date : 2024-01-25 DOI: 10.3760/cma.j.cn112141-20231018-00158
{"title":"[Guideline of diagnosis and management of amenorrhea (2023)].","authors":"","doi":"10.3760/cma.j.cn112141-20231018-00158","DOIUrl":"10.3760/cma.j.cn112141-20231018-00158","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"59 1","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression]. [高级浆液性卵巢癌中 ETAR mRNA 表达的临床意义及 ETAR 衍生融合多肽对癌症进展的抑制作用研究]。
Pub Date : 2023-12-25 DOI: 10.3760/cma.j.cn112141-20230801-00029
Y L Zhang, X K Xia, M Zhang

Objective: To investigate the clinical significance of endothelin A receptor (ETAR) expression in high-grade serous ovarian carcinoma (HGSOC). To design ETAR carboxyl terminal (ETAR-C) amino acids derived polypeptide and to study the inhibitory effect on ovarian epithelial carcinoma cells in vitro. Methods: (1) A total of 126 patients who received surgical treatment and were diagnosed with HGSOC by postoperative pathological examination in Central Hospital of Xuzhou from January 1, 2007 to December 31, 2017 were selected. All patients had completed clinicopathological data and follow-up data. Cancer tissue samples were collected and ETAR mRNA expression in HGSOC tissues was detected by reverse transcript-PCR. The clinical significance was analyzed. (2) ETAR-C fusion polypeptide was designed based on the sequence of carboxyl terminal amino acids of ETAR, expressed and purified in vitro. The effects of ETAR-C fusion polypeptide on migration and invasion ability of ovarian cancer SKOV3 and CAOV3 cells were detected by scratch test and invasion test, respectively. The effect of ETAR-C fusion polypeptide on chemosensitivity of cisplatin-resistant ovarian cancer SKOV3/cDDP and CAOV3/cDDP cells was determined by methyl thiazolyl tetrazolium (MTT) colorimetric assay. The effect of ETAR-C fusion polypeptide on β-arrestin-1 expression in ovarian cancer SKOV3 and CAOV3 cells was detected by western blot. Results: (1) The relative expression level of ETAR mRNA in HGSOC tissues was 18.6±5.1. Patients with HGSOC were divided into high ETAR mRNA expression (n=76) and low ETAR mRNA expression (n=50) with 61.7% as cut-off value analyzed by X-Tile software. High expression of ETAR mRNA was significantly correlated with abdominal water volume, platinum drug resistance, and cancer antigen 125 (CA125) value in HGSOC patients (all P<0.05), but was not related to the age of patients with HGSOC and the size of postoperative residual lesions (all P>0.05). The 5-year progression free survival rates were 18.4% and 28.0%, and the 5-year overall survival rates were 38.2% and 52.0% in HGSOC patients with high and low ETAR mRNA expression respectively, there were statistically significant differences (P=0.046, P=0.034). (2) The results of scratch test and invasion test showed that the scratch healing rate and cell invasion rate of SKOV3 or CAOV3 cells treated with endothelin-1 (ET-1) and ET-1+ETAR-C were respectively compared, and the differences were statistically significant (all P<0.05). MTT assay showed that the inhibition rates of ETAR-C fusion polypeptide treated in SKOV3/cDDP and CAOV3/cDDP cells were significantly higher than those of control cells after the addition of 4, 6, 8, 10, 12, and 24 μg/ml cisplatin (all P<0.05). Western blot analysis showed that the relative expression levels of β-arrestin-1 in SKOV3 or CAOV3 cells treated with ET-1 and ET-1+ETAR-C were 1.85±0.09 an

目的研究内皮素 A 受体(ETAR)在高级别浆液性卵巢癌(HGSOC)中表达的临床意义。设计 ETAR 羧基末端(ETAR-C)氨基酸衍生多肽,并在体外研究其对卵巢上皮癌细胞的抑制作用。方法:(1)选取2007年1月1日至2017年12月31日在徐州市中心医院接受手术治疗并经术后病理检查确诊为HGSOC的患者共126例。所有患者均有完整的临床病理资料和随访资料。收集肿瘤组织样本,通过逆转录-PCR检测ETAR mRNA在HGSOC组织中的表达。分析其临床意义。(2)根据 ETAR 羧基末端氨基酸序列设计了 ETAR-C 融合多肽,并在体外表达和纯化。通过划痕试验和侵袭试验分别检测了ETAR-C融合多肽对卵巢癌SKOV3和CAOV3细胞迁移和侵袭能力的影响。ETAR-C融合多肽对顺铂耐药卵巢癌SKOV3/cDDP和CAOV3/cDDP细胞化疗敏感性的影响采用甲基噻唑基四氮唑(MTT)比色法检测。免疫印迹法检测ETAR-C融合多肽对卵巢癌SKOV3和CAOV3细胞中β-arrestin-1表达的影响。结果:(1)ETAR mRNA在HGSOC组织中的相对表达水平为18.6±5.1。通过X-Tile软件分析,将HGSOC患者分为ETAR mRNA高表达组(n=76)和ETAR mRNA低表达组(n=50),以61.7%为临界值。ETAR mRNA的高表达与HGSOC患者的腹腔积水、铂类药物耐药性和癌抗原125(CA125)值显著相关(PP均>0.05)。ETAR mRNA高表达和低表达的HGSOC患者5年无进展生存率分别为18.4%和28.0%,5年总生存率分别为38.2%和52.0%,差异有统计学意义(P=0.046,P=0.034)。(2)划痕试验和侵袭试验结果显示,分别比较内皮素-1(ET-1)和ET-1+ETAR-C处理SKOV3或CAOV3细胞的划痕愈合率和细胞侵袭率,差异均有统计学意义(均为PPP结论:ETAR mRNA高表达的HGSOC患者的预后明显差于ETAR mRNA低表达的患者。ETAR可能是治疗HGSOC的新靶点。干扰ETAR与β-arrestin-1相互作用的ETAR-C融合多肽在体外对卵巢癌细胞有良好的抑制作用,可能具有临床应用潜力。
{"title":"[Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].","authors":"Y L Zhang, X K Xia, M Zhang","doi":"10.3760/cma.j.cn112141-20230801-00029","DOIUrl":"10.3760/cma.j.cn112141-20230801-00029","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the clinical significance of endothelin A receptor (ETAR) expression in high-grade serous ovarian carcinoma (HGSOC). To design ETAR carboxyl terminal (ETAR-C) amino acids derived polypeptide and to study the inhibitory effect on ovarian epithelial carcinoma cells in vitro. <b>Methods:</b> (1) A total of 126 patients who received surgical treatment and were diagnosed with HGSOC by postoperative pathological examination in Central Hospital of Xuzhou from January 1, 2007 to December 31, 2017 were selected. All patients had completed clinicopathological data and follow-up data. Cancer tissue samples were collected and ETAR mRNA expression in HGSOC tissues was detected by reverse transcript-PCR. The clinical significance was analyzed. (2) ETAR-C fusion polypeptide was designed based on the sequence of carboxyl terminal amino acids of ETAR, expressed and purified in vitro. The effects of ETAR-C fusion polypeptide on migration and invasion ability of ovarian cancer SKOV3 and CAOV3 cells were detected by scratch test and invasion test, respectively. The effect of ETAR-C fusion polypeptide on chemosensitivity of cisplatin-resistant ovarian cancer SKOV3/cDDP and CAOV3/cDDP cells was determined by methyl thiazolyl tetrazolium (MTT) colorimetric assay. The effect of ETAR-C fusion polypeptide on β-arrestin-1 expression in ovarian cancer SKOV3 and CAOV3 cells was detected by western blot. <b>Results:</b> (1) The relative expression level of ETAR mRNA in HGSOC tissues was 18.6±5.1. Patients with HGSOC were divided into high ETAR mRNA expression (<i>n</i>=76) and low ETAR mRNA expression (<i>n</i>=50) with 61.7% as cut-off value analyzed by X-Tile software. High expression of ETAR mRNA was significantly correlated with abdominal water volume, platinum drug resistance, and cancer antigen 125 (CA<sub>125</sub>) value in HGSOC patients (all <i>P</i><0.05), but was not related to the age of patients with HGSOC and the size of postoperative residual lesions (all <i>P</i>>0.05). The 5-year progression free survival rates were 18.4% and 28.0%, and the 5-year overall survival rates were 38.2% and 52.0% in HGSOC patients with high and low ETAR mRNA expression respectively, there were statistically significant differences (<i>P</i>=0.046, <i>P</i>=0.034). (2) The results of scratch test and invasion test showed that the scratch healing rate and cell invasion rate of SKOV3 or CAOV3 cells treated with endothelin-1 (ET-1) and ET-1+ETAR-C were respectively compared, and the differences were statistically significant (all <i>P</i><0.05). MTT assay showed that the inhibition rates of ETAR-C fusion polypeptide treated in SKOV3/cDDP and CAOV3/cDDP cells were significantly higher than those of control cells after the addition of 4, 6, 8, 10, 12, and 24 μg/ml cisplatin (all <i>P</i><0.05). Western blot analysis showed that the relative expression levels of β-arrestin-1 in SKOV3 or CAOV3 cells treated with ET-1 and ET-1+ETAR-C were 1.85±0.09 an","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"58 12","pages":"930-938"},"PeriodicalIF":0.0,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effects of preoperative diagnostic hysteroscopy on peritoneal cytology and prognosis in patients with non-endometrioid carcinoma]. [术前诊断性宫腔镜检查对非子宫内膜样癌患者腹腔细胞学和预后的影响]。
Pub Date : 2023-12-25 DOI: 10.3760/cma.j.cn112141-20230831-00080
Z Y Zhai, L Yang, H Li, L W Li, Z H Shen, X B Zhang, Z Q Wang, J L Wang
<p><p><b>Objective:</b> To explore the effects of preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage on the risk of abdominal dissemination and prognosis of non-endometrioid carcinoma. <b>Methods:</b> The clinical and pathological data of 97 patients who underwent surgical treatment and were pathologically confirmed as non-endometrioid carcinoma (including serous carcinoma, clear cell carcinoma, mixed adenocarcinoma, and undifferentiated carcinoma, etc.) from October 2008 to December 2021 in Peking University People's Hospital, were collected for retrospective analysis. According to preoperative diagnostic methods, they were divided into hysteroscopic group (<i>n</i>=44) and non-hysteroscopic group (<i>n</i>=53). The impact of hysteroscopy examination on peritoneal cytology and prognosis was analyzed. <b>Results:</b> (1) There were no statistical differences in age, body mass index, tumor size, pathological characteristics, and treatment methods between the hysteroscopic group and the non-hysteroscopic group (all <i>P</i>>0.05), but the proportion of stage Ⅰ-Ⅱ patients in the hysteroscopic group was significantly higher than that in the non-hysteroscopic group [68% (30/44) vs 47% (25/53); <i>χ</i><sup>2</sup>=4.32, <i>P</i>=0.038]. (2) Among 97 patients, 25 (26%, 25/97) of them were cytologically positive for ascites. The hysteroscopic group had a lower positive rate of peritoneal cytology than that in the non-hysteroscopy group, which was significantly different [11% (5/44) vs 38% (20/53); <i>χ</i><sup>2</sup>=8.74, <i>P</i>=0.003]. Stratification according to surgical and pathological stages showed that the positive rate of peritoneal cytology in the hysteroscopic group (3%, 1/30) was lower than that in the non-hysteroscopic group (12%, 3/25) in the 55 patients with stage Ⅰ-Ⅱ, and that in the hysteroscopic group (4/14) was also lower than that in the non-hysteroscopic group (61%, 17/28) in the 42 patients with stage Ⅲ-Ⅳ. There were no significant differences (all <i>P</i>>0.05). (3) The 5-year disease-free survival (DFS) rate of the hysteroscopic group and the non-hysteroscopic group were respectively 72.7% and 60.4%, and there was no significant difference between the two groups (<i>P</i>=0.186). After stratification according to staging, the 5-year DFS rate were respectively 90.0% and 72.0% (<i>P</i>=0.051) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅰ-Ⅱ, and 35.7% and 50.0% (<i>P</i>=0.218) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅲ-Ⅳ, in which there were not statistically significant differences. The 5-year overall survival (OS) rate were respectively 86.4% and 81.1% between the hysteroscopic group and the non-hysteroscopic group, with no significant difference between the two groups (<i>P</i>=0.388). The 5-year OS rate were respectively 93.3% and 96.0% in the hysteroscopic group and non-hysteroscopic group for patients with stage Ⅰ-Ⅱ(<i>P</i>=0.8
目的探讨术前宫腔镜引导下活检和分段诊断及刮宫对非子宫内膜样癌腹腔播散风险和预后的影响。方法:收集北京大学人民医院2008年10月至2021年12月接受手术治疗并经病理证实为非子宫内膜样癌(包括浆液性癌、透明细胞癌、混合型腺癌、未分化癌等)的97例患者的临床和病理资料,进行回顾性分析。根据术前诊断方法,分为宫腔镜组(44 例)和非宫腔镜组(53 例)。分析宫腔镜检查对腹腔细胞学和预后的影响。结果:(1)宫腔镜组与非宫腔镜组在年龄、体重指数、肿瘤大小、病理特征、治疗方法等方面无统计学差异(均P>0.05),但宫腔镜组Ⅰ-Ⅱ期患者比例明显高于非宫腔镜组[68%(30/44)vs 47%(25/53);χ2=4.32,P=0.038]。(2)97 例患者中,25 例(26%,25/97)腹水细胞学阳性。宫腔镜组腹水细胞学阳性率低于非宫腔镜组,差异显著[11% (5/44) vs 38% (20/53);χ2=8.74,P=0.003]。根据手术和病理分期进行的分层显示,宫腔镜组腹腔细胞学阳性率(3%,1/30)低于非宫腔镜组(12%,3/25)、在55例Ⅰ-Ⅱ期患者中,宫腔镜组的阳性率(3%,1/30)低于非宫腔镜组(12%,3/25);在42例Ⅲ-Ⅳ期患者中,宫腔镜组的阳性率(4/14)也低于非宫腔镜组(61%,17/28)。差异无学意义(P>0.05)。(3)宫腔镜组和非宫腔镜组的5年无病生存率(DFS)分别为72.7%和60.4%,两组间无显著差异(P=0.186)。根据分期进行分层后,Ⅰ-Ⅱ期患者宫腔镜组和非宫腔镜组的5年DFS率分别为90.0%和72.0%(P=0.051),Ⅲ-Ⅳ期患者宫腔镜组和非宫腔镜组的5年DFS率分别为35.7%和50.0%(P=0.218),差异无统计学意义。宫腔镜组和非宫腔镜组的5年总生存率分别为86.4%和81.1%,两组间差异无统计学意义(P=0.388)。对于Ⅰ-Ⅱ期患者,宫腔镜组和非宫腔镜组的5年生存率分别为93.3%和96.0%(P=0.872);对于Ⅲ-Ⅳ期患者,宫腔镜组和非宫腔镜组的5年生存率分别为71.4%和67.9%(P=0.999),差异无统计学意义。结论在本组患者中,诊断性宫腔镜检查并不会增加手术时腹腔细胞学结果的阳性率,术前宫腔镜检查与非子宫内膜样癌的不良预后之间也没有明显的相关性。因此,对非子宫内膜样癌进行术前宫腔镜引导活检和分段诊断及刮宫可能是安全的。
{"title":"[Effects of preoperative diagnostic hysteroscopy on peritoneal cytology and prognosis in patients with non-endometrioid carcinoma].","authors":"Z Y Zhai, L Yang, H Li, L W Li, Z H Shen, X B Zhang, Z Q Wang, J L Wang","doi":"10.3760/cma.j.cn112141-20230831-00080","DOIUrl":"10.3760/cma.j.cn112141-20230831-00080","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the effects of preoperative hysteroscopic guided biopsy and segmental diagnosis and curettage on the risk of abdominal dissemination and prognosis of non-endometrioid carcinoma. &lt;b&gt;Methods:&lt;/b&gt; The clinical and pathological data of 97 patients who underwent surgical treatment and were pathologically confirmed as non-endometrioid carcinoma (including serous carcinoma, clear cell carcinoma, mixed adenocarcinoma, and undifferentiated carcinoma, etc.) from October 2008 to December 2021 in Peking University People's Hospital, were collected for retrospective analysis. According to preoperative diagnostic methods, they were divided into hysteroscopic group (&lt;i&gt;n&lt;/i&gt;=44) and non-hysteroscopic group (&lt;i&gt;n&lt;/i&gt;=53). The impact of hysteroscopy examination on peritoneal cytology and prognosis was analyzed. &lt;b&gt;Results:&lt;/b&gt; (1) There were no statistical differences in age, body mass index, tumor size, pathological characteristics, and treatment methods between the hysteroscopic group and the non-hysteroscopic group (all &lt;i&gt;P&lt;/i&gt;&gt;0.05), but the proportion of stage Ⅰ-Ⅱ patients in the hysteroscopic group was significantly higher than that in the non-hysteroscopic group [68% (30/44) vs 47% (25/53); &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=4.32, &lt;i&gt;P&lt;/i&gt;=0.038]. (2) Among 97 patients, 25 (26%, 25/97) of them were cytologically positive for ascites. The hysteroscopic group had a lower positive rate of peritoneal cytology than that in the non-hysteroscopy group, which was significantly different [11% (5/44) vs 38% (20/53); &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=8.74, &lt;i&gt;P&lt;/i&gt;=0.003]. Stratification according to surgical and pathological stages showed that the positive rate of peritoneal cytology in the hysteroscopic group (3%, 1/30) was lower than that in the non-hysteroscopic group (12%, 3/25) in the 55 patients with stage Ⅰ-Ⅱ, and that in the hysteroscopic group (4/14) was also lower than that in the non-hysteroscopic group (61%, 17/28) in the 42 patients with stage Ⅲ-Ⅳ. There were no significant differences (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). (3) The 5-year disease-free survival (DFS) rate of the hysteroscopic group and the non-hysteroscopic group were respectively 72.7% and 60.4%, and there was no significant difference between the two groups (&lt;i&gt;P&lt;/i&gt;=0.186). After stratification according to staging, the 5-year DFS rate were respectively 90.0% and 72.0% (&lt;i&gt;P&lt;/i&gt;=0.051) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅰ-Ⅱ, and 35.7% and 50.0% (&lt;i&gt;P&lt;/i&gt;=0.218) between the hysteroscopic and non-hysteroscopic groups of patients in stage Ⅲ-Ⅳ, in which there were not statistically significant differences. The 5-year overall survival (OS) rate were respectively 86.4% and 81.1% between the hysteroscopic group and the non-hysteroscopic group, with no significant difference between the two groups (&lt;i&gt;P&lt;/i&gt;=0.388). The 5-year OS rate were respectively 93.3% and 96.0% in the hysteroscopic group and non-hysteroscopic group for patients with stage Ⅰ-Ⅱ(&lt;i&gt;P&lt;/i&gt;=0.8","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"58 12","pages":"903-910"},"PeriodicalIF":0.0,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华妇产科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1